Research Article: Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia

Date Published: August 11, 2011

Publisher: Public Library of Science

Author(s): Hsiu-Ni Kung, Jeffrey R. Marks, Jen-Tsan Chi, Matthew G. Vander Heiden

Abstract: Although significant variations in the metabolic profiles exist among different cells, little is understood in terms of genetic regulations of such cell type–specific metabolic phenotypes and nutrient requirements. While many cancer cells depend on exogenous glutamine for survival to justify the therapeutic targeting of glutamine metabolism, the mechanisms of glutamine dependence and likely response and resistance of such glutamine-targeting strategies among cancers are largely unknown. In this study, we have found a systematic variation in the glutamine dependence among breast tumor subtypes associated with mammary differentiation: basal- but not luminal-type breast cells are more glutamine-dependent and may be susceptible to glutamine-targeting therapeutics. Glutamine independence of luminal-type cells is associated mechanistically with lineage-specific expression of glutamine synthetase (GS). Luminal cells can also rescue basal cells in co-culture without glutamine, indicating a potential for glutamine symbiosis within breast ducts. The luminal-specific expression of GS is directly induced by GATA3 and represses glutaminase expression. Such distinct glutamine dependency and metabolic symbiosis is coupled with the acquisition of the GS and glutamine independence during the mammary differentiation program. Understanding the genetic circuitry governing distinct metabolic patterns is relevant to many symbiotic relationships among different cells and organisms. In addition, the ability of GS to predict patterns of glutamine metabolism and dependency among tumors is also crucial in the rational design and application of glutamine and other metabolic pathway targeted therapies.

Partial Text: There are a large number of differentiated cell types in the human body. Even among the cells collectively known as fibroblasts [1], endothelial [2] and smooth muscle cells [3], gene expression analysis has identified an unexpected level of positional memory and topographic differentiation. Such functional specialization contributes to the phenotypic variations of many human diseases, including cancer. For example, gene expression analysis of breast cancers has identified five intrinsic subtypes (luminal A, luminal B, basal, HER2+, and normal-like) with unique clinical and histological properties [4], [5]. The classification nomenclature is based on the putative progenitor cell(s) for breast carcinogenesis with properties consistent with derivation from the basal and luminal epithelia arrested at specific differentiation stages or from different mature epithelial cells [4]–[7]. Importantly, these subtype-specific gene expression and phenotypic variations are also observed in many breast cancer cell lines with similar molecular phenotypes [8]–[11]. A number of studies have isolated the different populations of primary epithelial cells to investigate their relevant cellular origins and metabolic features for different breast cancer types [7], [12], [13]. Although the cellular origin of luminal and basal-like breast tumor has not been resolved [14], [15], cell lineage still appears to confer an important source of patterned heterogeneity to the disease.

While glutamine has been shown to be critical in many cancer types, its importance for breast cancers is not well defined. In this study, we found a cell lineage-specific variation in the response of basal and luminal breast cancer cells to glutamine deprivation. The basal-type breast cancer cells are dependent on glutamine and exhibit a phenotype of glutamine addiction. Such a phenotype of basal cells was previously reported to be sensitive to inhibitors of glutaminase [27], trans-amination by aspartate aminotransferase [47] and selective estrogen receptor modulators [48]. In contrast, the luminal-type breast cancer cells are much more glutamine-independent. We present a series of data which strongly suggest that this phenotypic difference is related to the luminal-specific expression of glutamine synthetase (GS encoded by the GLUL gene) which is in turn regulated by one of the key luminal transcription factors, GATA3. Further, GS itself represses the expression of glutaminase (GLS) to reinforce the metabolic pathway in the direction of glutamine synthesis in luminal breast cells and the potential for glutamine symbiosis with basal breast cells.

Source:

http://doi.org/10.1371/journal.pgen.1002229